Activin a is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Chen, Weena J Y ^a   Greulich, Sabrina ^b,g   van der Meer, Rutger W ^c   Rijzewijk, Luuk J ^a   Lamb, Hildo J ^c   de Roos, Albert ^c   Smit, Johannes W A ^d   Romijn, Johannes A ^e   Ruige, Johannes B ^f   Lammertsma, Adriaan A ^a   Lubberink, Mark ^a,h   Diamant, Michaela ^a   Ouwens, D M ^b,f,g  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^h UPPSALA UNIVERSITY   (Sweden)

Author keywords

Activin A; Cardiac remodeling; Diabetic cardiomyopathy; Myocardial glucose metabolism

Indexed keywords

ACTIVIN A; FLUORODEOXYGLUCOSE F 18; GLUCOSE; METFORMIN; PIOGLITAZONE; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART SIZE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ACTIVINS; ADIPOSE TISSUE; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DOUBLE-BLIND METHOD; FLUORODEOXYGLUCOSE F18; GLUCOSE; HEART; HEART VENTRICLES; HUMANS; HYPOGLYCEMIC AGENTS; INHIBIN-BETA SUBUNITS; MAGNETIC RESONANCE IMAGING; MALE; METFORMIN; MIDDLE AGED; MYOCARDIUM; MYOCYTES, CARDIAC; ORGAN SIZE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84885545731     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-150     Document Type: Article

References (31)

1. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213-3223. 10.1161/CIRCULATIONAHA.106.679597, 17592090.
2. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, De Roos A, Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003, 42:328-335. 10.1016/S0735-1097(03)00625-9, 12875772.
3. Ouwens DM, Diamant M. Myocardial insulin action and the contribution of insulin resistance to the pathogenesis of diabetic cardiomyopathy. Arch Physiol Biochem 2007, 113:76-86. 10.1080/13813450701422633, 17558606.
4. Van Der Meer RW, Rijzewijk LJ, De Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, De Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009, 119:2069-2077. 10.1161/CIRCULATIONAHA.108.803916, 19349323.
5. Ouwens DM, Sell H, Greulich S, Eckel J. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med 2010, 14:2223-2234. 10.1111/j.1582-4934.2010.01141.x, 20716126.
6. Greulich S, Maxhera B, Vandenplas G, De Wiza DH, Smiris K, Mueller H, Heinrichs J, Blumensatt M, Cuvelier C, Akhyari P, Ruige JB, Ouwens DM, Eckel J. Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction. Circulation 2012, 126:2324-2334. 10.1161/CIRCULATIONAHA.111.039586, 23065384.
7. Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, Amour J, Leprince P, Dutour A, Clement K, Hatem SN. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 2013, Epub ahead of print. doi:10.1093/eurheartj/eht099.
8. Rijzewijk LJ, Van Der Meer RW, Lamb HJ, De Jong HW, Lubberink M, Romijn JA, Bax JJ, De Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, Diamant M. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009, 54:1524-1532. 10.1016/j.jacc.2009.04.074, 19815124.
9. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
10. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
11. Knaapen P, Boellaard R, Gotte MJ, Dijkmans PA, van Campen LM, de Cock CC, Luurtsema G, Visser CA, Lammertsma AA, Visser FC. Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy. J Nucl Med 2004, 45:1299-1304.
12. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations J Cereb Blood Flow Metab 1985, 5:584-590.
13. Rijzewijk LJ, Van Der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, De Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:1793-1799. 10.1016/j.jacc.2008.07.062, 19022158.
14. Zhao CT, Wang M, Siu CW, Hou YL, Wang T, Tse HF, Yiu KH. Myocardial dysfunction in patients with type 2 diabetes mellitus: role of endothelial progenitor cells and oxidative stress. Cardiovasc Diabetol 2012, 11:147. 10.1186/1475-2840-11-147, 3537556, 23217199.
15. Fredersdorf S, Thumann C, Zimmermann WH, Vetter R, Graf T, Luchner A, Riegger GA, Schunkert H, Eschenhagen T, Weil J. Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data. Cardiovasc Diabetol 2012, 11:57. 10.1186/1475-2840-11-57, 3447673, 22621761.
16. Chen WJ, Rijzewijk LJ, Van Der Meer RW, Heymans MW, Van Duinkerken E, Lubberink M, Lammertsma AA, Lamb HJ, De Roos A, Romijn JA, Smit JW, Bax JJ, Bjerre M, Frystyk J, Flyvbjerg A, Diamant M. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol 2011, 10:67. 10.1186/1475-2840-10-67, 3157422, 21771299.
17. Smith C, Yndestad A, Halvorsen B, Ueland T, Waehre T, Otterdal K, Scholz H, Endresen K, Gullestad L, Froland SS, Damas JK, Aukrust P. Potential anti-inflammatory role of activin A in acute coronary syndromes. J Am Coll Cardiol 2004, 44:369-375. 10.1016/j.jacc.2004.03.069, 15261933.
18. Yndestad A, Ueland T, Oie E, Florholmen G, Halvorsen B, Attramadal H, Simonsen S, Froland SS, Gullestad L, Christensen G, Damas JK, Aukrust P. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004, 109:1379-1385. 10.1161/01.CIR.0000120704.97934.41, 14993131.
19. Ueland T, Aukrust P, Aakhus S, Smith C, Endresen K, Birkeland KI, Gullestad L, Johansen OE. Activin A and cardiovascular disease in type 2 diabetes mellitus. Diab Vasc Dis Res 2012, 9:234-237. 10.1177/1479164111431171, 22234949.
20. Andersen GO, Ueland T, Knudsen EC, Scholz H, Yndestad A, Sahraoui A, Smith C, Lekva T, Otterdal K, Halvorsen B, Seljeflot I, Aukrust P. Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation. Diabetes 2011, 60:1544-1551. 10.2337/db10-1493, 3292329, 21464440.
21. Weigert J, Neumeier M, Wanninger J, Schober F, Sporrer D, Weber M, Schramm A, Wurm S, Stogbauer F, Filarsky M, Schaffler A, Aslanidis C, Scholmerich J, Buechler C. Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes. Cytokine 2009, 45:86-91. 10.1016/j.cyto.2008.10.017, 19128983.
22. Wu H, Wu M, Chen Y, Allan CA, Phillips DJ, Hedger MP. Correlation between Blood Activin Levels and Clinical Parameters of Type 2 Diabetes. Exp Diabetes Res 2012, 2012:410579. 3533484, 23304117.
23. Kumar SD, Dheen ST, Tay SS. Maternal diabetes induces congenital heart defects in mice by altering the expression of genes involved in cardiovascular development. Cardiovasc Diabetol 2007, 6:34. 10.1186/1475-2840-6-34, 2176054, 17967198.
24. Zhao Z. Cardiac malformations and alteration of TGFbeta signaling system in diabetic embryopathy. Birth Defects Res B Dev Reprod Toxicol 2010, 89:97-105.
25. Zhao Z. Activin-a in diabetes-induced cardiac malformations in embryos. Birth Defects Res B Dev Reprod Toxicol 2013, 98:260-267. 10.1002/bdrb.21060, 23716477.
26. Blumensatt M, Greulich S, Herzfeld De Wiza D, Mueller H, Maxhera B, Rabelink MJ, Hoeben RC, Akhyari P, Al Hasani H, Ruige JB, Ouwens DM. Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143. Cardiovasc Res 2013, Epub ahead of print. doi:10.1093/cvr/cvt173.
27. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144-2150. 10.1001/jama.288.17.2144, 12413374.
28. Werner S, Alzheimer C. Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev 2006, 17:157-171. 10.1016/j.cytogfr.2006.01.001, 16481210.
29. Zaragosi LE, Wdziekonski B, Villageois P, Keophiphath M, Maumus M, Tchkonia T, Bourlier V, Mohsen-Kanson T, Ladoux A, Elabd C, Scheideler M, Trajanoski Z, Takashima Y, Amri EZ, Lacasa D, Sengenes C, Ailhaud G, Clement K, Bouloumie A, Kirkland JL, Dani C. Activin a plays a critical role in proliferation and differentiation of human adipose progenitors. Diabetes 2010, 59:2513-2521. 10.2337/db10-0013, 3279533, 20530742.
30. Ofstad AP, Gullestad L, Orvik E, Aakhus S, Endresen K, Ueland T, Aukrust P, Fagerland MW, Birkeland KI, Johansen OE. Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Baerum Cardiovascular Diabetes (ABCD) cohort study. Cardiovasc Diabetol 2013, 12:126. 10.1186/1475-2840-12-126, 3766106, 23987834.
31. Yndestad A, Haukeland JW, Dahl TB, Bjoro K, Gladhaug IP, Berge C, Damas JK, Haaland T, Loberg EM, Linnestad P, Birkeland K, Konopski Z, Halvorsen B, Berge RK, Aukrust P. A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol 2009, 104:2196-2205. 10.1038/ajg.2009.318, 19532130.